Vanguard Group Inc Karuna Therapeutics, Inc. Transaction History

Vanguard Group Inc

  • $5.46 Trillion
  • Q3 2024

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 14, 2024
BUY
$161.01 - $317.85 $3.41 Million - $6.74 Million
21,201 Added 0.66%
3,224,786 $1.02 Billion
Q3 2023

Nov 14, 2023
BUY
$164.66 - $218.08 $17.4 Million - $23 Million
105,686 Added 3.41%
3,203,585 $542 Million
Q2 2023

Aug 14, 2023
BUY
$176.32 - $240.22 $13.8 Million - $18.8 Million
78,353 Added 2.59%
3,097,899 $672 Million
Q1 2023

May 15, 2023
BUY
$161.33 - $204.36 $42.9 Million - $54.4 Million
266,003 Added 9.66%
3,019,546 $548 Million
Q4 2022

Feb 10, 2023
BUY
$191.53 - $236.82 $25.3 Million - $31.3 Million
131,958 Added 5.03%
2,753,543 $541 Million
Q3 2022

Nov 14, 2022
BUY
$123.79 - $277.42 $55.6 Million - $125 Million
448,871 Added 20.66%
2,621,585 $590 Million
Q2 2022

Aug 12, 2022
BUY
$93.97 - $143.33 $4.85 Million - $7.39 Million
51,562 Added 2.43%
2,172,714 $275 Million
Q1 2022

May 13, 2022
BUY
$98.9 - $132.37 $3.64 Million - $4.87 Million
36,816 Added 1.77%
2,121,152 $269 Million
Q4 2021

Feb 14, 2022
BUY
$110.64 - $159.4 $2.1 Million - $3.02 Million
18,945 Added 0.92%
2,084,336 $273 Million
Q3 2021

Nov 12, 2021
BUY
$101.2 - $125.87 $5.02 Million - $6.25 Million
49,641 Added 2.46%
2,065,391 $253 Million
Q2 2021

Aug 13, 2021
BUY
$107.45 - $135.95 $217 Million - $274 Million
2,015,750 New
2,015,750 $230 Million

Others Institutions Holding KRTX

# of Institutions
10
Shares Held
332K
Call Options Held
0
Put Options Held
0
View Full List

About Karuna Therapeutics, Inc.

KRTX Quotes by TradingView
  • Ticker KRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 33,965,000
  • Description
  • Karuna Therapeutics, Inc., a clinical-stage biopharmaceutical company, creates and delivers transformative medicines for people living with psychiatric and neurological conditions. Its lead product candidate is KarXT, an oral modulator of muscarinic receptors that is in Phase III clinical trial for the treatment of acute psychosis in patients wi...
More about KRTX
Track This Portfolio

Track Vanguard Group Inc Portfolio

Follow Vanguard Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vanguard Group Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email